News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

2007 Credit Suisse Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Presentation


11/6/2007 10:34:48 AM

CAMBRIDGE, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that its presentation at the 2007 Credit Suisse Healthcare Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The presentation will include an overview of the Company, an update on clinical trials for VELCADE(R) (bortezomib) for Injection and other product candidates, and a review of upcoming milestones. The presentation will be delivered at 1:00 p.m. ET on Tuesday, November 13, 2007 from the Arizona Biltmore Resort in Phoenix, Arizona. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company's website is http://www.millennium.com.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.

Contact:

Kyle Kuvalanka

(617) 761-4734



CONTACT: Kyle Kuvalanka of Millennium Pharmaceuticals, Inc.,
+1-617-761-4734

Web site: http://www.millennium.com/

Company News On-Call: http://www.prnewswire.com/comp/114562.html /


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES